Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
Children's National Research Institute
Children's National Research Institute
National Cancer Institute (NCI)
Emory University
UniversitƤtsklinikum Hamburg-Eppendorf
Bayer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
National Cancer Institute (NCI)
Children's Oncology Group
MacroGenics
Children's Oncology Group
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Emory University
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)
Nationwide Children's Hospital
University of Michigan Rogel Cancer Center
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
University of Louisville
Fred Hutchinson Cancer Center
Children's Oncology Group
Barbara Ann Karmanos Cancer Institute
SillaJen, Inc.
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Laboratorio Elea Phoenix S.A.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Indiana University
University of Minnesota
Children's Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins